A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Results (n=18) assessing efficacy presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 20 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.